Insomnia and sleep apnea contribute to reports of cognitive decline in women with multiple sclerosis.

Published Date: 22 Mar 2023

In women with multiple sclerosis who have mental illness (one of the most common symptoms of the disease), sleep disturbances such as insomnia and sleep apnea may decrease.

Read Full News

Latest News

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

8 Pulmonology Headlines You Missed in September 2026

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

News All Time

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Bridging the ROS1 Divide: Translating Biomarker Insights and Therapeutic Advances Into Community Oncology Practice for NSCLC

Recommended News For You

New study elucidates obesity's role in fueling breast cancer progression

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.

Asian Women With Breast Cancer Outlive White Peers

Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer

Some triple negative breast cancers might be avoided by longer breastfeeding

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Recommended Articles For You

Exploring the Unknown: Unveiling the Mysteries of GIST Tumors 

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options  

Neutrophil Profiling and AI Rewrites Cancer Diagnosis 

Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

Breast cancer-related fatigue: The benefits of adapted physical activity

4.

'Converging' Evidence of Link Between Air Pollution and Breast Cancer

5.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

1.

Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions

2.

Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms 

3.

Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked

4.

Exploring the Impact of Adrenal Myelolipoma on the Human Body

5.

Innovative Methods in Oncology in the Digital Era

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Importance of Cancer Screening and Early Detection

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

3.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

4.

Signs and Symptoms of Leukemia

5.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot